<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pmed.1002882.t004" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pmed.1002882.t004</object-id>
 <label>Table 4</label>
 <caption>
  <title>Ongoing and planned TB clinical trials in HIV-infected persons 12 years and older (as of December 2018).</title>
 </caption>
 <alternatives>
  <graphic id="pmed.1002882.t004g" xlink:href="pmed.1002882.t004" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" rowspan="1" colspan="1">Study/Trial Number</th>
     <th align="left" rowspan="1" colspan="1">Funding/ Sponsor</th>
     <th align="left" rowspan="1" colspan="1">Phase</th>
     <th align="left" rowspan="1" colspan="1">TB Type</th>
     <th align="left" rowspan="1" colspan="1">Purpose</th>
     <th align="left" rowspan="1" colspan="1">Design</th>
     <th align="left" rowspan="1" colspan="1">Regimen</th>
     <th align="left" rowspan="1" colspan="1">Study Population</th>
     <th align="left" rowspan="1" colspan="1">Location</th>
     <th align="left" rowspan="1" colspan="1">Status</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td align="left" colspan="10" rowspan="1">LTBI</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">WHIP3TB/NCT02980016</td>
     <td align="left" rowspan="1" colspan="1">USAID</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">Efficacy of 3HP given once or annually to reduce TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">Part A: 6H versus 3HP; part B: 3HP once versus annually</td>
     <td align="left" rowspan="1" colspan="1">Adults, adolescents, children (2+ years old), 
      <bold>HIV+ on ART 3+ months or not eligible for ART, any CD4</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa, Mozambique, Ethiopia</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">TBTC37</td>
     <td align="left" rowspan="1" colspan="1">CDC</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">LTBI</td>
     <td align="left" rowspan="1" colspan="1">Efficacy and safety of 6 weeks of HP daily</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">6 weeks daily HP versus 3HP versus 4HR daily versus 4R daily</td>
     <td align="left" rowspan="1" colspan="1">Adults and adolescents (12+ years old), 
      <bold>HIV+</bold>/−, on 
      <bold>compatible ART, any CD4</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">US, TBTC international sites TBD</td>
     <td align="left" rowspan="1" colspan="1">In development</td>
    </tr>
    <tr>
     <td align="left" colspan="10" rowspan="1">DS TB</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">NCT03563599</td>
     <td align="left" rowspan="1" colspan="1">Qurient</td>
     <td align="left" rowspan="1" colspan="1">IIa</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Assess early bactericidal activity of Telacebec</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">Multiple doses of Telacebec (Q203) versus Rifafour e-275 (RHZE)</td>
     <td align="left" rowspan="1" colspan="1">Adult (18–65 years old), new treatment-naïve smear-positive DS TB, 
      <bold>no HIV exclusion criteria stated</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Enrollment complete March 19, 2019</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">ReDEFINe/NCT02169882</td>
     <td align="left" rowspan="1" colspan="1">Universitas Padjadjaran, USAID</td>
     <td align="left" rowspan="1" colspan="1">IIb</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Dose finding for R to treat TB meningitis</td>
     <td align="left" rowspan="1" colspan="1">Double-blind randomized trial</td>
     <td align="left" rowspan="1" colspan="1">Standard dose versus R
      <sub>(900)</sub> or R
      <sub>(1350)</sub> + HEZ ×6 months
     </td>
     <td align="left" rowspan="1" colspan="1">Adults (15+ years old), no pregnancy/breastfeeding, on ATT &lt;3 days with clinical suspicion of TBM
      <bold>, no HIV exclusion criteria stated</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Indonesia</td>
     <td align="left" rowspan="1" colspan="1">In data analysis</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">APT/NCT02256696</td>
     <td align="left" rowspan="1" colspan="1">FDA</td>
     <td align="left" rowspan="1" colspan="1">IIb</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Mycobacterial activity of Pa824</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">Pa824
      <sub>(200)</sub> ×12 weeks added to HRZ
     </td>
     <td align="left" rowspan="1" colspan="1">Adults (18+ years old); HIV−/
      <bold>HIV+ CD4 ≥350 cells/mm</bold>
      <sup>
       <bold>3</bold>
      </sup>
      <bold>and not on ART</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">ACTG5362 CLOFAST</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID</td>
     <td align="left" rowspan="1" colspan="1">IIc</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Dose finding for C to treat DS TB</td>
     <td align="left" rowspan="1" colspan="1">Double-blind randomized trial</td>
     <td align="left" rowspan="1" colspan="1">(4C
      <sub>50</sub> versus 4C
      <sub>100</sub> versus 4placebo) + 4HP
      <sub>1200</sub>ZE/2placebo versus 2placebo versus 2HP
     </td>
     <td align="left" rowspan="1" colspan="1">Adults (18+ years old), no pregnancy/ breastfeeding, 
      <bold>HIV+ CD4 ≥ 100 cells/mm</bold>
      <sup>
       <bold>3</bold>
      </sup>
      <bold>, compatible ARV or about to start</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">ACTG sites TBD</td>
     <td align="left" rowspan="1" colspan="1">In development</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">NCT02836483</td>
     <td align="left" rowspan="1" colspan="1">LegoChem Biosciences</td>
     <td align="left" rowspan="1" colspan="1">II</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Early bactericidal activity, safety, and PK of oral delpazolid</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">Multiple doses of delpazolid versus Li</td>
     <td align="left" rowspan="1" colspan="1">Korean adults (19–70 years old) with smear-positive pulmonary TB.
      <break/>
      <bold>No HIV exclusion criteria stated</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Korea</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">TBTC Study 31 ACTG 5349/NCT02410772</td>
     <td align="left" rowspan="1" colspan="1">AIDS Clinical Trials Group, CDC</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DS</td>
     <td align="left" rowspan="1" colspan="1">Efficacy of 2 shortened rifapentine-containing regimens for pulmonary TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized, controlled clinical trial</td>
     <td align="left" rowspan="1" colspan="1">Standard 6-month regimen versus 4-month regimen substituting P for R versus 4-month regimen substituting P for R and M for E</td>
     <td align="left" rowspan="1" colspan="1">Children and adults (12 years+), AFB or GeneXpert-positive, documented HIV status, 
      <bold>if HIV+ CD4 &gt; 100 cells/mm</bold>
      <sup>
       <bold>3</bold>
      </sup>
     </td>
     <td align="left" rowspan="1" colspan="1">USA, Brazil, China, Haiti, India, Kenya, Malawi, Peru, South Africa, Thailand, Uganda, Vietnam, Zimbabwe</td>
     <td align="left" rowspan="1" colspan="1">Enrollment completed. Follow-up ongoing.</td>
    </tr>
    <tr>
     <td align="left" colspan="10" rowspan="1">DR TB</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">ACTG 5356</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID</td>
     <td align="left" rowspan="1" colspan="1">IIa</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Dose-finding for Li in all oral regimens for MDR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">Li (600 qd/1,200 qd) + Bdq200 +De200 + Le (if FQ S) or C (if FQ R)</td>
     <td align="left" rowspan="1" colspan="1">Adults and adolescents (&gt;12 years old); 
      <bold>if HIV+ CD4 ≥ 50 cells/mm</bold>
      <sup>
       <bold>3</bold>
      </sup>
     </td>
     <td align="left" rowspan="1" colspan="1">ACTG sites
      <break/>TBD
     </td>
     <td align="left" rowspan="1" colspan="1">In development</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">TBTC Study 32, OPTI-Q NCT01918397</td>
     <td align="left" rowspan="1" colspan="1">CDC, NIH NIAID</td>
     <td align="left" rowspan="1" colspan="1">II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Efficacy, safety, and tolerability of using Le in regimen for MDR TB</td>
     <td align="left" rowspan="1" colspan="1">Blinded, randomized PK/PD trial</td>
     <td align="left" rowspan="1" colspan="1">4 doses of Le + OBR</td>
     <td align="left" rowspan="1" colspan="1">Adults (18+ years old), smear-positive/culture-positive MDR TB; 
      <bold>HIV</bold>+ 
      <bold>included must have viral load and CD4 count within 3 months</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Peru, South Africa</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">ACTG 5343/NCT02583048</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID</td>
     <td align="left" rowspan="1" colspan="1">II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Safety, tolerability, and PK of BDQ and De (alone and in combination) + OBR for RR/MDR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">6 months of BDQ + OBR versus De + OBR versus BDQ + De + OBR; dolutegravir + 2 NRTIs for HIV+ only</td>
     <td align="left" rowspan="1" colspan="1">Adults (18+ years old), documented RR/MDR pulmonary TB, documented HIV status, if 
      <bold>HIV+</bold>: 
      <bold>CD4 &gt; 100 cells/mm</bold>
      <sup>
       <bold>3</bold>
      </sup>
      <bold>and one fully active NRTI available if on ART &gt;6 months and viral load &gt; 500 copies/mL</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Peru, South Africa</td>
     <td align="left" rowspan="1" colspan="1">Active, not recruiting</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">MDR END/NCT02619994</td>
     <td align="left" rowspan="1" colspan="1">University Seoul, Korea</td>
     <td align="left" rowspan="1" colspan="1">II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Safety, efficacy of shortened injection-free regimen for MDR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized controlled clinical trial</td>
     <td align="left" rowspan="1" colspan="1">De + Le + Li + Z x 9 or 12 months versus 24 OBR</td>
     <td align="left" rowspan="1" colspan="1">Adults 19+ years old, no FQ resistance, 
      <bold>no HIV exclusion criteria stated</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Korea</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">SODOCU</td>
     <td align="left" rowspan="1" colspan="1">EDCTP</td>
     <td align="left" rowspan="1" colspan="1">II</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Dose-finding study of U</td>
     <td align="left" rowspan="1" colspan="1">Open-label dose-finding trial</td>
     <td align="left" rowspan="1" colspan="1">3U (0 mg qd + 600 mg qd versus 1,200 mg qd versus 600 mg bid versus 800 mg bid) + 3BdqDeM</td>
     <td align="left" rowspan="1" colspan="1">Adults</td>
     <td align="left" rowspan="1" colspan="1">TBD</td>
     <td align="left" rowspan="1" colspan="1">In development</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">SimpliciTB/NCT03338621</td>
     <td align="left" rowspan="1" colspan="1">Global Alliance for TB Drug Development</td>
     <td align="left" rowspan="1" colspan="1">II/III</td>
     <td align="left" rowspan="1" colspan="1">DS/DR</td>
     <td align="left" rowspan="1" colspan="1">Efficacy, safety, and tolerability of a new, shorter oral regimen for DS/DR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, partially randomized trial</td>
     <td align="left" rowspan="1" colspan="1">DS TB:
      <break/>BDQPaMoZ ×4 months versus HRZE/HR ×6 months;
      <break/>DR TB:
      <break/>BdqPaMoZ ×6 months
     </td>
     <td align="left" rowspan="1" colspan="1">Adults (18+ years old), new smear-positive DS/DR TB; 
      <bold>HIV+ criteria</bold>: 
      <bold>CD &gt;100 cells/mm</bold>
      <sup>
       <bold>3</bold>
      </sup>, Karnofsky score &gt;60%, no IV antifungal in past 90 days, and WHO clinical stage &lt;4 disease
     </td>
     <td align="left" rowspan="1" colspan="1">10 countries in Africa, Asia, Europe, and South America</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">TB PRACTECAL/NCT02589782</td>
     <td align="left" rowspan="1" colspan="1">MSF, Global Alliance for TB Drug Development, WHO, THINK</td>
     <td align="left" rowspan="1" colspan="1">II/III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Safety (Phase II) and efficacy (Phase III) of short regimens containing B and Pa for MDR/XDR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized trial</td>
     <td align="left" rowspan="1" colspan="1">6 months of BdqPaLiMo, BdqPaLiC, or BdqPaLi versus local WHO SOC MDR/XDR TB regimen</td>
     <td align="left" rowspan="1" colspan="1">Adults (18+ years old), with microbiologically confirmed TB resistant to at least R; 
      <bold>HIV+ included regardless of status</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Belarus, South Africa, Uzbekistan</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">NExT-5001/NCT02454205</td>
     <td align="left" rowspan="1" colspan="1">University of Cape Town</td>
     <td align="left" rowspan="1" colspan="1">II/III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Efficacy, safety, tolerability of shortened, injection-free regimen for MDR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized controlled clinical trial</td>
     <td align="left" rowspan="1" colspan="1">LiBdqLeZ + E or high-dose H ×6–9 months versus conventional empiric injection-based 21–24 month regimen</td>
     <td align="left" rowspan="1" colspan="1">Adults (18+ years old), new culture or GeneXpert-positive MDR TB; 
      <bold>if HIV+ CD4 &gt; 50 cells/mm</bold>
      <sup>
       <bold>3</bold>
      </sup>
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">ACTG 5273 FIRST</td>
     <td align="left" rowspan="1" colspan="1">NIH NIAID</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Efficacy of new regimens for H monoresistant TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized clinical trial</td>
     <td align="left" rowspan="1" colspan="1">6H 15mg/kg RZE versus 2RZELe/2RLe</td>
     <td align="left" rowspan="1" colspan="1">Adults, adolescents, and children; 
      <bold>any CD4, any ARV</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">ACTG sites TBD</td>
     <td align="left" rowspan="1" colspan="1">In development</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">STREAM/NCT02409290</td>
     <td align="left" rowspan="1" colspan="1">IUATLD</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Efficacy of different regimens for MDR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized clinical trial</td>
     <td align="left" rowspan="1" colspan="1">Local 2011 WHO MDR TB regimen versus CEMZ ×40 weeks + H, kanamycin, prothionamide × first 16 weeks versus 40 weeks oral regimen BdqCELeZ + H and prothionamide × first 16 weeks versus 28 weeks BdqCLeZ + H and kanamycin × first 8 weeks</td>
     <td align="left" rowspan="1" colspan="1">Adult (15+ years old), AFB or GeneXpert positive, resistant to rifampicin and isoniazid, 
      <bold>if HIV+: willing to start ART and CD4 &gt; 50 cells/mm</bold>
      <sup>
       <bold>3</bold>
      </sup>
     </td>
     <td align="left" rowspan="1" colspan="1">Ethiopia, Georgia, India, Republic of Moldava, Mongolia South Africa, Uganda</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">Nix-TB (B-Pa-L)/NCT02333799</td>
     <td align="left" rowspan="1" colspan="1">Global Alliance for TB Drug Development</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Safety, efficacy, tolerability, and PK of BDQ + Li ×6 months for MDR/XDR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label trial</td>
     <td align="left" rowspan="1" colspan="1">6–9 months of BdqPaLi</td>
     <td align="left" rowspan="1" colspan="1">Children and adults (14+ years old), XDR TB or nonresponsive MDR TB, culture-positive, documented HIV status, 
      <bold>if HIV+ CD4 &gt; 50 cells/mm</bold>
      <sup>
       <bold>3</bold>
      </sup>
     </td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">All enrolled</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">ZeNix NC-007/NCT03086486</td>
     <td align="left" rowspan="1" colspan="1">Global Alliance for TB Drug Development</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Safety and efficacy of various doses and treatment duration of Li + Pa + BDQ for MDR, pre-XDR, and XDR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, partially blinded, randomized clinical trial; even allocation across arms by HIV status and TB type</td>
     <td align="left" rowspan="1" colspan="1">Li
      <sub>(1,200)</sub> ×26 weeks + Pa + BDQ versus Li
      <sub>(1,200)</sub> ×9 weeks + Pa + BDQ versus Li
      <sub>(600)</sub> ×26 weeks + Pa + BDQ versus Li
      <sub>(600)</sub> ×9 weeks + Pa + BDQ
     </td>
     <td align="left" rowspan="1" colspan="1">Children and adults (14+ years old), documented HIV status, culture or molecular test positive and documented resistance, 
      <bold>if HIV+ CD4 &gt; 100cells/mm</bold>
      <sup>
       <bold>3</bold>
      </sup>
     </td>
     <td align="left" rowspan="1" colspan="1">Georgia, Republic of Moldova, Russian Federation, South Africa</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">endTB/NCT02754765</td>
     <td align="left" rowspan="1" colspan="1">UNITAID</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Evaluating newly approved oral, shortened regimens for MDR TB (FQ sensitive)</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized, controlled noninferiority clinical trial</td>
     <td align="left" rowspan="1" colspan="1">BdqLiMoZ ×39 weeks
      <break/>BdqLiCLeZ ×39 weeks
      <break/>BdqDeLiLeZ ×39 weeks
      <break/>DeLiCLeZ ×39 weeks
      <break/>DeCMoZ ×39 weeks versus control (Z)
     </td>
     <td align="left" rowspan="1" colspan="1">Children and adults (15+ years old) with documented pulmonary MTB resistant to R, 
      <bold>no HIV exclusion criteria stated</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">Georgia, Kazakhstan, Kyrgyzstan, Lesotho, Peru, and South Africa</td>
     <td align="left" rowspan="1" colspan="1">Enrolling</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">endTB-Q</td>
     <td align="left" rowspan="1" colspan="1">UNITAID/MSF</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Evaluating newly approved oral, shortened regimens for MDR TB (FQ sensitive)</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized, controlled noninferiority clinical trial</td>
     <td align="left" rowspan="1" colspan="1">6BdqDeLiC versus 10BdqDeLiC versus OBR</td>
     <td align="left" rowspan="1" colspan="1">Children and adults (15+ years old) with documented pulmonary MTB resistant to R; 
      <bold>no HIV exclusion criteria stated</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">India, Pakistan, Kazakhstan, Lesotho, Peru</td>
     <td align="left" rowspan="1" colspan="1">In development</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">BEAT TB</td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Safety and efficacy of short regimen for MDR TB</td>
     <td align="left" rowspan="1" colspan="1">Strategy trial</td>
     <td align="left" rowspan="1" colspan="1">6BdqDeLeLi
      <sub>600</sub>C (drop Li if FQ sensitive; drop Le if FQ resistant)
     </td>
     <td align="left" rowspan="1" colspan="1">Adults</td>
     <td align="left" rowspan="1" colspan="1">South Africa</td>
     <td align="left" rowspan="1" colspan="1">In development</td>
    </tr>
    <tr>
     <td align="left" rowspan="1" colspan="1">DRAMATIC/NCT03828201</td>
     <td align="left" rowspan="1" colspan="1">US Department of Defense</td>
     <td align="left" rowspan="1" colspan="1">III</td>
     <td align="left" rowspan="1" colspan="1">DR</td>
     <td align="left" rowspan="1" colspan="1">Efficacy and tolerability of shortened injection-free regimen for MDR TB</td>
     <td align="left" rowspan="1" colspan="1">Open-label, randomized controlled clinical trial</td>
     <td align="left" rowspan="1" colspan="1">4BdqDeLe
      <sub>1000</sub>Li
      <sub>1200</sub>C versus 6BdqDeLe
      <sub>1000</sub>Li
      <sub>1200</sub>C versus 2011 WHO regimen
     </td>
     <td align="left" rowspan="1" colspan="1">Adults and adolescents 12+ years old, HIV−/ 
      <bold>HIV+ any CD4</bold>
     </td>
     <td align="left" rowspan="1" colspan="1">TBD</td>
     <td align="left" rowspan="1" colspan="1">In development</td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="t004fn001">
   <p>Data in this table obtained from clinical trials.gov and adapted from a table compiled by Michael J. Vjecha, MD, on behalf of TBTC Core Science Group.</p>
  </fn>
  <fn id="t004fn002">
   <p>Abbreviations: 3HP, 3 months of weekly isoniazid and rifapentine; ACTG, AIDS Clinical Trials Group; AFB, acid-fast bacilli; ART, antiretroviral therapy; ARV, antiretroviral; ATT, antituberculosis therapy; Bdq, bedaquiline; C, clofazimine; CDC, Centers for Disease Control and prevention; De, delamanid; E, ethambutol; EDCTP, European &amp; Developing Countries Clinical Trials Partnership; FDA, Food and Drug Administration; FQ, fluoroquinolone; HIV, human immunodeficiency virus; H, isoniazid; IUATLD, International Union Against Tuberculosis and Lung Disease (The Union); Le, levofloxacin; Li, linezolid; LTBI, latent TB infection; MDR, multidrug-resistant; Mo, moxifloxacin; MSF, Médecins Sans Frontières; NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health; NRTI, nucleoside reverse transcriptase inhibitor; OBR, optimized background regimen; P, rifapentine; Pa, pretomanid; PD, pharmacodynamics; PK, pharmacokinetics; R, rifampicin; RR, rifampicin-resistant; s, sensitive; SOC, standard of care; TB, tuberculosis; TBD, to be determined; TBTC, Tuberculosis Trials Consortium; THINK, TB&amp;HIV Investigative Network; U, sutezolid; USAID, United States Agency for International Development; WHO, World Health Organization; XDR, extremely drug-resistant; Z, pyrazinamide</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
